Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642076 | 0.99 | HRH3 (0.51) | HRH3EPHX2P2RX7LIPGSSTR3 | |
| SCHEMBL1641788 | 0.79 | EGLN3 (0.52) | HRH3SSTR3ALDH1A1HPGDAPEX1 | |
| SCHEMBL1641480 | 0.78 | EGLN3 (0.52) | HRH3SSTR3ALDH1A1HPGDAPEX1 | |
| SCHEMBL1642205 | 0.78 | EGLN3 (0.52) | HRH3SSTR3ALDH1A1HPGDAPEX1 | |
| SCHEMBL1640776 | 0.77 | NPC1 (0.50) | P2RX7MEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL1641375 | 0.76 | HSP90AA1 (0.53) | MEN1ALDH1A1KMT2AHPGDAPEX1 | |
| SCHEMBL1641394 | 0.75 | CNR1 (0.53) | HRH3MEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL1640586 | 0.74 | TSHR (0.50) | P2RX7LIPGMEN1ALDH1A1KMT2A | |
| SCHEMBL1641080 | 0.74 | LMNA (0.47) | MEN1ALDH1A1KMT2AAPEX1HSP90AA1 | |
| SCHEMBL1641802 | 0.73 | NPC1 (0.50) | MEN1ALDH1A1KMT2AHPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2306828-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxosmithkline LLC (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | HRH3 442/4885EPHX2 993/4885P2RX7 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.